Pre-clinical and clinical experience of telmisartan in cardiac remodelling

Journal of International Medical Research

Volumn 33, Issue SUPPL. 1, 2005, Pages

  Verdecchia, P ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Angiotensin II receptor bloker; Left ventricular hypertrophy; Renin angiotension system; Telmisartan

Indexed keywords

AMILORIDE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; RAMIPRIL; TELMISARTAN; VALSARTAN;

ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLLAGEN SYNTHESIS; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; DRUG TARGETING; FIBROBLAST CULTURE; HEART ATRIUM FUNCTION; HEART FUNCTION; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; NONHUMAN; OUTCOMES RESEARCH; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 25844519026     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/14732300050330s103     Document Type: Article

References (43)

1. Levy D: Left ventricular hypertrophy. Epidemiological insights from the Framingham Heart Study. Drugs 1988; 35 (Suppl 5): 1-5.
2. Benjamin EJ, Levy D: Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 1999; 317: 168-175.
3. Verdecchia P, Procellati C, Reboldi G, Gattobigio R, Borgioni C, Pearson V, et al: Left ventricular hypertrophy as an independent predictor of acute cerebrovascular events in essential hypertension. Circulation 2001; 104: 2039-2044.
4. Verdecchia P, Carini G, Circo A, Dovellini E, Giovannini E, Lombardo M, et al: Left ventricular mass and cardiovascular morbidity in essential hypertension: the MAVI study. J Am Coll Cardiol 2001; 38: 1829-1835.
5. Laufer E, Jennings GL, Korner PI, Dewar E: Prevalence of cardiac structural and functional abnormalities in untreated primary hypertension. Hypertension 1989; 13: 151-162.
6. Schillaci G, Verdecchia P, Porcellati C, Cuccurullo O, Cosco C, Perticone F: Continuous relation between left ventricular mass and cardiovascular risk in essential hypertension. Hypertension 2000; 35: 580-586.
7. Verdecchia P, Schillaci G, Boldrini F, Guerrieri M, Gatteschi C, Benemio G, et al: Risk stratification of left ventricular hypertrophy in systemic hypertension using noninvasive ambulatory blood pressure monitoring. Am J Cardiol 1990; 66: 583-590
8. Verdecchia P, Schillaci G, Borgioni C, Ciucci A, Sacchi N, Battistelli M, et al: Gender, day-night blood pressure changes, and left ventricular mass in essential hypertension. Dippers and peakers. Am J Hypertens 1995; 8: 193-196.
9. Ikeda T, Yamamoto K, Okada J, Hayashidad M, Yamada C, Kasatani T, et al: Morning rise in blood pressure associates with hypertensive cardiovascular complications. J Hypertens 2002; 20 (Suppl 4): S150.
10. Matsuo K, Kosugi T, Kamiya H, Yoshii K, Okada J, Gomi T, et al: Morning rise in blood pressure as risk factor for cardiovascular complications in treated hypertensive patients. J Hypertens 2002; 20 (Suppl 4): S314.
11. Schmieder RE, Messerli FH: Hypertension and the heart. J Hum Hypertens 2000; 14: 597-604.
12. Verdeccia P, Angeli F, Pittavini L, Gattobigio R, Benemio G, Porcellatti C: Regression of left ventricular hypertrophy and cardiovascular risk changes in hypertensive patients. Ital Heart J 2004; 5: 505-510.
13. Verdecchia P, Angeli F, Borgioni C, Gattobigio R, de Simone G, Devereux RB, et al: Changes in cardiovascular risk by reduction of left ventricular mass in hypertension: a meta-analysis. Am J Hypertens 2003; 16: 895-899.
14. Guidelines Subcommittee: 1999 World Health Organization - International Society of Hypertension guidelines for the management of hypertension. J Hypertens 1999; 17: 151-183.
15. Klingbeil A, Schneider M, Martus P, Messerli F, Schmieder R: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115: 41-46.
16. White WB, Lacourcière Y, Davidai G: Effects of the angiotensin II receptor blockers telmisartan versus valsartan on the circadian variation of blood pressure. Impact on the early morning period. Am J Hypertens 2004; 17: 347-353.
17. Lacourciere Y, Krzesinski JM, White WB, Davidai G, Schumacher H: Sustained anti-hypertensive activity of telmisartan compared with valsartan. Blood Press Monit 2004; 9: 203-210.
18. Stangier J, Su CAPF, Roth W: Pharmacokinetics of orally and intravenously administered telmisartan in healthy young and elderly volunteers and in hypertensive patients. J Int Med Res 2000; 28: 149-167.
19. Wienen W, Entzeroth M, van Meel JCA, Stangier J, Busch U, Ebner T, et al: A review on telmisartan: a novel, long-acting angiotensin II-receptor antagonist. Cardiovasc Drug Rev 2000; 18: 127-156.
20. González A, López B, Díez J: Fibrosis in hypertensive heart disease: role of the renin - angiotensin - aldosterone system. Med Clin North Am 2004; 88: 83-97.
21. Lijnen PJ, Petrov VV, Fagard RH: Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst 2001; 2: 117-122.
22. Nolly HL, Osso PA, Nolly MB: Role of AT2 receptor in the protective effect of telmisartan in cardiac tissue. Am J Hypertens 2004; 17: 158A.
23. Wagner J, Drab M, Bohlender J, Amann K, Wienen W, Ganten D: Effects of AT1 receptor blockade on blood pressure and the renin - angiotensin system in spontaneously hypertensive rats of the stroke prone strain. Clin Exp Hypertens 1998; 20: 205-221.
24. Bohm M, Lippoldt A, Wienen W, Ganten D, Bader M: Reduction of cardiac hypertrophy in TGR(mREN2)27 by angiotensin II receptor blockade. Mol Cell Biochem 1996; 163/164: 217-221.
25. Amende I, Chu V, Morgan JP, Hampton TG: Angiotensin II AT1 receptor blockade attenuates isoproterenol-induced cardiac hypertrophy in mice. Eur Heart J 2000; 21 (Abstract Suppl): 401.
26. Wienen W, Richard S, Champeroux P, Audeval-Gerard C: Comparative antihypertensive and renoprotective effects of telmisartan and lisinopril after long-term treatment in hypertensive diabetic rats. J Renin Angiotensin Aldosterone Syst 2001; 2: 31-36.
27. Mattioli AV, Zennaro M, Bonatti S, Bonetti L, Mattioli G: Regression of left ventricular hypertrophy and improvement of diastolic function in hypertensive patients treated with telmisartan. Int J Cardiol 2004; 97: 383-388.
28. Alizade IG, Alieva-Karaeva NT: Long-term effects of Pritor on left ventricular mass and diastolic function in hypertensive patients. J Hypertens 2002; 20 (Suppl 4): S340.
29. Martina B, Dieterle T, Sigle J-P, Surber C, Battegay E: Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial. Cardiology 2003; 99: 169-170.
30. Gopal AS, Schnellbaecher MJ, Shen Z, Boxt LM, Katz J, King DL: Freehand three-dimensional echocardiography for determination of left ventricular volume and mass in patients with abnormal ventricles: comparison with magnetic resonance imaging. J Am Soc Echocardiogr 1997; 10: 853-861.
31. Bachenberg TC, Shub C, Hauck AJ, Edwards WD: Can anatomical left ventricular mass be estimated reliably by M-mode echocardiography? A clinicopathological study of ninety-three patients. Echocardiography 1991; 8: 9-15.
32. Galzerano D, Tammaro P, Cerciello A, Breglio R, Mallardo M, Lama D, et al: Freehand three-dimensional echocardiographic evaluation of the effect of telmisartan compared with hydrochlorothiazide on left ventricular mass in hypertensive patients with mild-to-moderate hypertension: a multicentre study. J Hum Hypertens 2004; 18: 53-59.
33. Galzerano D, Del Viscovo L, Tammaro P, Cerciello A, Breglio R, Mallardo M, et al: Multicentre randomized study on the effect of telmisartan compared to carvedilol on LV mass: three dimensional echocardographic and magnetic resonance assessment. J Hypertens 2004; 22 (Suppl 2): S112.
34. Delgado AJ, Delgado-Almeida AR, Celis SI, Delgado-León CL: Improved LV function, systemic vascular and brachial artery parameters in hypertension: the Venezuelan telmisartan study. Am J Hypertens 2001; 14 (Suppl 1): A127.
35. Tudorica C, Muraru M, Moise M, Tudorica S, Bruckner I: The assessment of left ventricular systolic function in patients with hypertensive cardiopathy and ischaemic heart disease. J Hypertens 2004; 22 (Suppl 2): S258.
36. Delgado AJ, Delgado-Leon CL: Acute effect of AT1 receptor blocker telmisartan on arterial stiffness and left ventricular function. Am J Hypertens 2002; 17 (5 Pt 2): 104A.
37. Celis SI, Delgado AJ, Galves ES, Delgado-León CL, Delgado-Almeida AR: Hemodynamic differences among AT1 receptor blockers in arterial hypertension: results with valsartan and telmisartan. Am J Hypertens 2002; 15 (4 Pt 2): 72A.
38. Delgado AJ, Delgado-Almeida AR, Celis SI: AT1 receptor blocker and diuretics in the treatment of arterial hypertension: hemodynamic differences. Am J Hypertens 2002; 15 (4 Pt 2): 72A.
39. Erol MK, Yilmaz M, Acikel M, Karakelleoglu S: Left atrial mechanical function in patients with essential hypertension. Acta Cardiol 2002; 57: 323-327.
40. Mattioli AV, Bonatti S, Zennaro M, Monopoli D, Mattioli G: Effects of regression of left ventricular hypertrophy on left atrial size and function. Am J Hypertens 2003; 16: 177A.
41. Jacobi J, Schlaich MP, Delles C, Schobel HP, Schmieder RE: Angiotensin II stimulates left ventricular hypertrophy in hypertensive patients independently of blood pressure. Am J Hypertens 1999; 12: 418-422.
42. Teo K, Yusuf S, Anderson C, Mookadam F, Ramos B, Hilbrich L, et al: Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 2004; 148: 52-61.
43. Anderson C: Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme. J Int Med Res 2005; 33 (Suppl 1): 50A-57A.